Epidarex Capital
Venture capitalBethesda · Pre-Seed–Series A · 9 people tracked
Also known as EPIDAREX CAPITAL MANAGEMENT LLC · EPIDAREX CAPITAL US
Investment thesis
Epidarex is a transatlantic early-stage venture capital firm that invests in and helps build breakthrough life science companies located in emerging innovation hubs. Led by a diverse team of early-stage investors, the firm positions itself as a trusted partner to founders and co-investors, leveraging deep scientific and industry networks to create value and drive shared success across its portfolio.
Source: firm website, verified Aug 3, 2026.
Team · 9 people
from public directories
What they invest in
from 21 of 39 portfolio companiesBiotech ×19Medical Devices ×15Healthtech ×7AI & Machine Learning ×4Digital Health ×3Deep Tech ×2Longevity ×1
HQs:United States×6United Kingdom×1
Investments · 39 tracked
founders shown can be your intro pathLUNAC Therapeutics develops first-in-class oral and intravenous anticoagulants targeting activated Factor XII to treat and prevent thrombotic events with reduced bleeding risk.
BiotechHealthtechMedical DevicesLeeds, GB
Professor Helen Philippou(Scientific Founder)Dr. Richard Foster(Scientific Founder)
Technology-focused company on rational drug design for cancer and chronic inflammatory diseases (acquired by Aclaris Therapeutics in August 2017).
HealthtechSaint Louis, US
Daniel Janiak(Director)Jennifer Bohnert(Executive Officer)Walter Smith(Executive Officer, Director)Joseph Monahan(Executive Officer, Director)Charles Bolten(Director)Thomas Smart(Director)
Board seatKyparissia Sirinakis· per SEC Form D
University of Maryland spin-out commercializing minimally invasive image-guided surgical tool for beating heart mitral valve repair (acquired by Edwards Lifesciences in December 2017).
BiotechBaltimore, US
Mark Collins(Executive Officer)James Cox(Director)James Gammie(Director)Peter Boyd(Executive Officer)William Niland(Executive Officer, Director)
Board seatKyparissia Sirinakis· per SEC Form D
Slate Bio develops regulatory T cell (Treg) therapies for treating autoimmune diseases.
BiotechDigital HealthMedical DevicesCharlottesville, US
Robert Creeden(Director)Kurt Woerpel(Executive Officer)Kyparissia Sirinakis(Director)Andrew J Krouse(Executive Officer, Director)
Board seatKyparissia Sirinakis· per SEC Form D
Developing new modulators of the adenosine pathway for cancer treatment.
NASDAQ-listed company developing therapies for complement cascade-driven diseases in haematology, ophthalmology, and nephrology.
University of Glasgow spin-out with pioneering CellOPTIQ technology to evaluate cardiotoxicity risk in pharmaceuticals.
Clyde Biosciences provides a human iPSC-derived cardiomyocyte platform called CellOPTIQ® that enables earlier detection of cardiovascular risk and cardiotoxicity assessment for pharmaceutical and biotech companies during drug development.
BiotechHealthtechMedical Devices
Curve Therapeutics develops cyclic peptide and small molecule drugs using its Microcycle discovery platform to target intracellular disease mechanisms.
AI & Machine LearningBiotechDeep Tech
Developing next-generation small molecule therapeutics based on differentiated protein degradation technology.
University of Edinburgh spin-out clinical-phase biotech developing C-Met molecular targeting technology for cancer radiotherapy and imaging.
Enterprise Therapeutics develops novel drug therapies targeting the underlying mechanisms of mucus congestion in respiratory diseases including cystic fibrosis, asthma, and COPD.
BiotechHealthtechMedical Devices
RNA-targeted company focused on upregulating new targets to transform treatment of neurodegenerative diseases.
Harness Therapeutics develops precision therapies for neurodegenerative diseases including Huntington's, Parkinson's, Alzheimer's, and ALS through its proprietary protein modulation platform.
AI & Machine LearningBiotechMedical Devices
Emory University spin-out developing novel nucleic acid-based targeted delivery platform for cancer therapeutics.
Kodikaz develops Zip-Code, a non-viral cell-specific delivery platform for gene therapy applications, particularly focused on oncology and cancer treatments.
AI & Machine LearningBiotechMedical DevicesAtlanta, US
Anthony Johnson(Co-Founder & CEO)inDr. Leon Bernal-Mizrachi(Co-Founder, CSO)in
University of Edinburgh spin-out immunemetabolic company with expertise in the kynurenine pathway and KMO biology.
Preclinical-stage drug discovery company co-founded by Epidarex-Exeed and Axxam developing first-in-class precision medicines for epileptic and neurological disorders.
Lario Therapeutics develops first-in-class precision medicines for severe neurological disorders, including epileptic encephalopathies and Parkinson's disease.
BiotechDigital Health
Leucid Bio develops a proprietary Lateral CAR platform for chimeric antigen receptor T-cell (CAR-T) therapies in oncology.
AI & Machine LearningBiotechMedical Devices
John Maher
Libra Therapeutics develops small molecule therapeutics targeting lysosomal function and autophagy to treat neurodegenerative diseases including ALS, Parkinson's, Alzheimer's, and Huntington's disease.
BiotechLongevityMedical Devices
Dr. Gill(Chief Scientific Officer)
Nyra Medical develops the CARLEN System, a transcatheter device for single-leaflet repair of functional mitral regurgitation that preserves native valve function.
BiotechDigital HealthMedical DevicesAtlanta, US
Dr. Murali Padala(Founder)Dr. Eric Sarin(Founder)Dr. Kirthana Suresh(Founder)Lori Chmura(CEO)Sai Muralidhar Padala(Executive Officer, Director)Amrinder Singh(Director)
Medical technology company developing next-generation stroke aspiration technology
Medical device company developing novel aspiration system to treat ischemic stroke.
Medical Devices
Ryme Medical develops a catheter-based therapy to treat chronic obstructive pulmonary disease (COPD) by reducing airway inflammation and improving patient outcomes.
BiotechHealthtechMedical DevicesMountain View, US
University of Aberdeen spin-out developing nano-synthetic bone graft substitutes using advanced nanostructures for bone repair (acquired November 2020).
Theolytics develops oncolytic adenovirus-based immunotherapies to overcome the tumor microenvironment barriers in solid cancers.
BiotechDeep TechMedical Devices
Topas Therapeutics develops a nanoparticle platform technology to establish immune tolerance in autoimmune and immune-mediated diseases.
BiotechMedical Devices
Frequently asked questions
- What stage does Epidarex Capital invest at?
- Epidarex Capital invests at the Pre-Seed, Seed, Series A stages.
- What is Epidarex Capital's typical check size?
- Epidarex Capital typically writes checks of $2.5M – $6.3M.
- What sectors does Epidarex Capital focus on?
- Epidarex Capital focuses on Biotech, Digital Health, Healthtech, Medical Devices.
- Where is Epidarex Capital located?
- Epidarex Capital is headquartered in Bethesda, US.
- Does Epidarex Capital lead rounds?
- Yes, Epidarex Capital leads investment rounds.
Media · Podcasts & interviews
featuring the teamDr Peter Finan, BIA Board Member, Partner, Epidarex Capital on SVB collapse
BioIndustry Association - BIA · Peter Finan
Similar investors
Amadeus Capital Partners is a UK-based deep tech venture capital firm founded in 1997 that invests from seed to growth stages across artificial intelligence, health, and sustainability-focused technologies.
B Capital Group is a global venture capital firm that backs founders from early to late stage, with dedicated stage-based funds and a portfolio spanning technology, healthcare, and energy and resilience sectors.
Breyer Capital is a venture capital firm that backs high-impact entrepreneurs, making strategic investments guided by founder passion and its network of experienced investors.
DCVC (Data Collective) is a venture capital firm that backs founders building companies which apply technology to major challenges across areas such as energy, biotech, agriculture, and machine learning.
Future Positive Capital is an investment firm backing entrepreneurs building companies that address major global challenges and shape more sustainable, preferable futures.